Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: Clinical benefit from cinacalcet

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages

  Reh, Christina M S ^a   Hendy, Geoffrey N ^b   Cole, David E C ^c   Jeandron, Debra D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; FUROSEMIDE; GENOMIC DNA; INFUSION FLUID; PAMIDRONIC ACID; PARATHYROID HORMONE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM EXCRETION; CASE REPORT; CONGENITAL HYPERPARATHYROIDISM; DRUG EFFICACY; EXON; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HETEROZYGOUS MUTATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERPARATHYROIDISM; INFANT; LONG TERM CARE; MOLECULAR PATHOLOGY; NEWBORN DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; AMINO ACID SUBSTITUTION; ARGININE; CALCIMIMETIC AGENTS; FEMALE; GLUTAMIC ACID; HETEROZYGOTE; HUMANS; HYPERPARATHYROIDISM; INFANT, NEWBORN; MALE; MOLECULAR SEQUENCE DATA; NAPHTHALENES; POINT MUTATION; RECEPTORS, CALCIUM-SENSING; TREATMENT OUTCOME;

EID: 79953864293     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1306     Document Type: Article

References (34)

1. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC 1993 Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575-580 (Pubitemid 24035999)
2. Brown EM 2000 Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. EndocrinolMetab Clin North Am 29:503-522
3. Hendy GN, Guarnieri V, Canaff L 2009 Calcium-sensing receptor and associated diseases. Prog Mol Biol Transl Sci 89:31-95
4. Cole DE, Janicic N, Salisbury SR, Hendy GN 1997 Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: Multiple different phenotypes associated with an inactivating Alu insertion mutation of the calciumsensing receptor (CASR) gene. Am J Med Genet 71:202-210
5. Pearce S, Steinmann B 1999 Casting new light on the clinical spectrum of neonatal severe hyperparathyroidism. Clin Endocrinol (Oxf) 50:691-693 (Pubitemid 29284501)
6. Hsu SC, LevineMA2004 Perinatal calcium metabolism: Physiology and pathophysiology. Semin Neonatol 9:23-36 (Pubitemid 38112117)
7. Nemeth EF, Fox J 1999 Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10:66-71 (Pubitemid 29287825)
8. Wüthrich RP, Martin D, Bilezikian JP 2007 The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37: 915-922 (Pubitemid 350151180)
9. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D 2009 Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 94:4860-4867
10. Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR 2006 Normalization of serum calcium by cinacalcet in a patient with hypercalcemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 260:177-182 (Pubitemid 44051343)
11. Festen-Spanjer B, Haring CM, Koster JB, Mudde AH 2008 Correction of hypercalcemia by cinacalcet in familial hypocalciuric hypercalcemia. Clin Endocrinol (Oxf) 68:324-325
12. Cole DE, Yun FH, Wong BY, Shuen AY, Booth RA, Scillitani A, Pidasheva S, Zhou X, Canaff L, Hendy GN 2009 Calcium-sensing receptor (CASR) mutations and denaturing high performance liquid chromatography (DHPLC). J Mol Endocrinol 42:331-339
13. Pollak MR, Brown EM, Chou YH, Hebert SC, Marx SJ, Steinmann B, Levi T, Seidman CE, Seidman JG 1993 Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297-1303
14. Pearce SH, Trump D, Wooding C, BesserGM,Chew SL, Heath DA, Hughes IA, Paterson CR, WhyteMP1995 Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 96:2683-2692
15. Heath 3rd H, Odelberg S, Jackson CE, Teh BT, Hayward N, Larsson C, Buist NR, Krapcho KJ, Hung BC, Capuano IV, Garrett JE, Leppert MF 1996 Clustered inactivating mutations and benign polymorphisms of the calcium-sensing receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J Clin Endocrinol Metab 81:1312-1317 (Pubitemid 26118553)
16. Bai M, Pearce SH, Kifor O, Trivedi S, Stauffer UG, Thakker RV, Brown EM, Steinmann B 1997 In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: Normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J Clin Invest 99:88-96 (Pubitemid 27058298)
17. Sarli M, Fradinger E, Zanchetta J 2004 Hypocalciuric hypercalcemia due to a de novo mutation of the calcium-sensing receptor. Medicina (Buenos Aires) 64:337-339 (Pubitemid 40360850)
18. Obermannova B, Banghova K, Sumnik Z, Dvorakova HM, Betka J, Fencl F, Kolouskova S, Cinek O, Lebl J 2009 Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur J Pediatr 168: 569-573
19. Huang Y, Zhou Y, Castiblanco A, Yang W, Brown EM, Yang JJ 2009 Multiple Ca2+-binding sites in the extracellular domain of the Ca2+-sensing receptor corresponding to cooperativeCa2+response. Biochemistry 48:388-398
20. Bai M, Quinn S, Trivedi S, Kifor O, Pearce SH, Pollak MR, Krapcho K, Hebert SC, Brown EM 1996 Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J Biol Chem 271:19537-19454
21. Pidasheva S, Grant M, Canaff L, Ercan O, Kumar U, Hendy GN 2006 The calcium-sensing receptor (CASR) dimerizes in the endoplasmic reticulum: Biochemical and biophysical characterization of novel CASR mutations causing familial hypocalciuric hypercalcemia. Hum Mol Genet 15:2200-2209 (Pubitemid 43985511)
22. Bai M, Trivedi S, Kifor O, Quinn SJ, Brown EM 1999 Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function. Proc Natl Acad Sci USA 96:2834-2839 (Pubitemid 29148804)
23. Wystrychowski A, Pidasheva S, Canaff L, Chudek J, Kokot F, Wiecek A, HendyGN2005 Functional characterization of calciumsensing receptor codon 227 mutations presenting either as familial (benign) hypocalciuric hypercalcemia or neonatal hyperparathyroidism. J Clin Endocrinol Metab 90:864-870 (Pubitemid 40279210)
24. Zajickova K, Vrbikova J, Canaff L, Pawelek PD, Goltzman D, Hendy GN 2007 Identification and functional characterization of a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia: Modulation of clinical severity by vitamin D status. J Clin Endocrinol Metab 92:2616-2623 (Pubitemid 47037366)
25. Meeran K, Husain M, Puccini M, Scott H, Dionisi-Vici C, Harvey DR, Lynn J, Thakker RV 1994 Neonatal primary hyperparathyroidism masked by vitamin D deficiency. Clin Endocrinol (Oxf) 41:531-534 (Pubitemid 24301288)
26. Allgrove J 2002 Use of bisphosphonates in children and adolescents. J Pediatr Endocrinol Metab 15(Suppl 3):921-928
27. Waller S, Kurzawinski T, Spitz L, Thakker R, Cranston T, Pearce S, Cheetham T, van't Hoff WG 2004 Neonatal severe hyperparathyroidism: Genotype/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr 163:589-594 (Pubitemid 39362535)
28. Fox L, Sadowsky J, Pringle KP, Kidd A, Murdoch J, Cole DE, Wiltshire E 2007 Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant. Pediatrics 120: E1350-e1354 (Pubitemid 350085578)
29. Gensure RC Use of bisphosphonates in an 8 week old child with a calcium sensing receptor defect. Program of the 82nd Annual Meeting of The Endocrine Society, Toronto, Canada, 2000, Meet-the-Professor Handouts, p 380
30. Alon US, VanDeVoorde RG 2010 Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Pediatr Nephrol 25:1747-1750
31. Rus R, Haag C, Bumke-Vogt C, Bähr V, Mayr B,MöhligM,Schulze E, Frank-Raue K, Raue F, Schöfl C 2008 Novel inactivating mutations of the calcium-sensing receptor: The calcimimetic NPS R-568 improves signal transduction of mutant receptors. J Clin Endocrinol Metab 93:4797-4803
32. Lu JY, Yang Y, Gnacadja G, Christopoulos A, Reagan JD 2009 Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1- propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. J Pharmacol Exp Ther 331:775-786
33. Huang Y, Breitwieser GE 2007 Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J Biol Chem 282:9517-9525 (Pubitemid 47104573)
34. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. 2000CDC growth charts: United States advance data from vital and health statistics, no. 314. Hyattsville, MD: National Center for Health Statistics